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ABSTRACT 
The aim of this work was to develop a mucoadhesive buccal tablet for the buccal delivery of the alendronate via buccal mucosa. Buccal tablets of 
alendronate are designed to release drug at mucosal site for extended period of time without wash out of drug by saliva. Alendronate sodium is 
a bisphosphonates which has antiresorptive effect which is implicated in the prophylaxis and treatment of osteoporosis. Sodium alginate, ethyl 
cellulose and carbopol were selected as mucoadhesive polymers on the basis of their matrix forming properties. The objective of the study is to 
improve the bioavailability of alendronate buccal tablets. Extensive literature survey was done for the collection of theoretical and technical 
data. The methodology part includes the explanation of implemented methods in the present study. In present study, an attempt was made to 
design mucoadhesive buccal tablets containing alendronate, sodium alginate, ethyl cellulose and carbopol using as polymers. The tablets were 
prepared by direct compression method. The formulations were evaluated for hardness, thickness, friability, weight variation,  drug content 
estimation, surface pH determination, swelling index, in vitro drug release. In vitro bioadhesive strength & in vitro release studies showed that 
formulation F11 showed optimum bioadhesive & exhibited optimum drug release 97.6% in 7hr. Kinetics results reveals that the F11 
formulation follows zero order kinetics as correlation coefficient (r2) values are higher than that of first- order release kinetics.Optimized 
formula F11 show drug is released by non-Fickian diffusion mechanism. The stability studies of formulation F11 prepared mucoadhesive buccal 
tablets of alendronate were stable. Overall evaluations of the mucoadhesive of tablets show good mucoadhesive properties.  
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INTRODUCTION: 
Mucoadhesive drug delivery systems: 
Since the early 1980s, the concept of mucoadhesion has 
gained considerable interest in pharmaceutical technology 
[1]. Adhesion can be defined as the bond produced by 
contact between a pressure sensitive adhesive and a surface. 
The American society of testing and materials has defined it 
as the state in which two surfaces are held together by 
interfacial forces, which may consist of valence forces, 
interlocking action or both. Mucoadhesive drug delivery 
systems prolong the residence time of the dosage form at the 
site of application or absorption. They facilitate an intimate 
contact of the dosage form with the underlying absorption 
surface and thus improve the therapeutic performance of the 
drug [2-3]. In recent years, many such mucoadhesive drug 
delivery systems have been developed for oral, buccal, nasal, 
rectal and vaginal routes for both systemic and local 
effects.[4]  The mucoadhesive drug delivery system includes 
the following: [5] .1. Buccal drug delivery system. 2. Oral 
delivery system. 3. Vaginal delivery system. 4. Rectal delivery 
system. 5. Nasal delivery system. 6. Ocular delivery system 
Alendronate has a positive influence on all symptoms of 
osteoporosis by increasing bone mineral density and patient 
mobility, reducing the risk of osteoporotic fractures in all 
vulnerabilities (vertebrae, hip, arm and femoral neck) and 
having an analgesic effect in bone pain.   Alendronate sodium 
is a bisphosphonates which has anti resorptive effect which 
is implicated in the prophylaxis and treatment of 
osteoporosis. Alendronate sodium is a BCS class III 
bisphosphonate, which acts as a potent, specific inhibitor of 
osteoclast-mediated bone resorption. However, low oral 
bioavailability (under 1%) is the most important 
disadvantage of alendronate sodium. It is caused by several 
factors such as: low permeability due to its negatively 
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charged molecules (belongs to the III class of 
biopharmaceutical classification system); short plasma half-
time (T½ = 0.5-2 h); its chelatation by Ca2+ ions resulting in 
non-absorbable complexes. Research in bisphosphonates in 
general aims to increase the bioavailability of these 
substances, to decrease side effects, to increase adherence to 
treatment especially for elderly patients[6-8]. 
In this study we have investigated the possibility of 
improving the oral bioavailability of alendronate by buccal 
tablet containing sodium alginate, ethyl cellulose and 
carbopol using as polymer. 
MATERIALS AND METHODS: 
Materials: Materials used for this formulation obtained from 
different sources. Alendronate is provided by Chandra labs, 
hydroxyl propyl methyl cellulose (HPMC), Micro crystalline 
cellulose, Guar gum procured from NRchem, Mumbai. 
Sodium alginate procured from Karnataka fine chem., 
Bangalore. Ethyl Cellulose (EC), Talk, PVP K-30 procured 
from S.D. Fine Chem. Ltd, Mumbai, India. 
METHODS: 
Pre formulation studies: 
Pre-formulation is defined as study of physical and chemical 
properties of a drug substance alone prior to formulation. 
The overall objective of pre-formulation studies is to 
generate information useful to the formulator in developing 
stable dosage forms. The results of Preformulation are given 
table no-02 
Formulation of mucoadhesive tablets of alendronate: 
In this work, direct compression method has been employed 
to prepare buccal tablet with different polymers because 
with the dry granulation and wet granulation the hardness of 
tablets has increased because of which rate of drug release 
got decreased. For one tablet accurately weighed 300 mg 
was used in the formulation. All the ingredients were 
accurately weighed and passed through mesh # 60. In order 
to mix all ingredients thoroughly drug, polymers, micro 
crystalline cellulose, aspartame were blended geometrically 
in mortar and pestle for 10 minutes then magnesium 
stearate and talc were mixed for 1-2 min. The powder blends 
of various proportions were evaluated for angle of repose, 
carr’s compressibility index and compressed into tablets of 
diameter 9mm on cadmach press16 Station machine. Using 
stainless steel flat surface dies and punches by maintaining 
individual tablet weight constant at 300 mg [9-10]. 
 
Table 1: Composition of alendronate buccal tablets 
Ingredients (mg) F1 F2 F3 F4 F5 F6      F7 F8 F9 F10 F11 F12 
 
Alendronate 40 40 40 40 40 40 40 40 40 40 40 40 
Sodium alginate 
 
15 - - - - - - - - - - - 
Carbopol 
 
- 15 - 22.5 - 15 7.5 22.5 7.5 30 - 15 
EC 
 
- - 15 - 22.5 7.5 15 7.5 22.5 - 30 15 
Talc 
 
7.5 7.5 7.5 7.5 7.5 7.5 7.5 7.5 7.5 7.5 7.5 7.5 
PVP k-30 
 
7.5 7.5 7.5 7.5 7.5 7.5 7.5 7.5 7.5 7.5 7.5 7.5 
MS 
 
7.5 7.5 7.5 7.5 7.5 7.5 7.5 7.5 7.5 7.5 7.5 7.5 
MCC 
 
q.s q.s q.s q.s q.s q.s q.s q.s q.s q.s q.s q.s 
Aspartame  
 
3 3 3 3 3 3 3 3 3 3 3 3 
Total weight 300 300 300 300 300 300 300 300 300 300 300 300 
 
Micrometrics properties: 
The blends for buccoadhesive tablets were characterized 
with respect to angle of repose, bulk density, tapped density, 
carr’s index, and hausner’s ratio. Angle of repose was less 
than 30° and Carr’s index values were less than 20 for the 
blend of all the batches indicating excellent to good 
flowability and compressibility. Hausner’s ratio was less than 
1.25 for all the batches indicating excellent flow properties 
[11]. The outcome are given table no-03. 
Compatibility studies: 
To investigate any possible interactions between the drug 
and excipients used, the FT-IR spectra of pure drug 
alendronate and physical mixture of optimized formulation F 
11 by using thermo electron corporation (Nicolet IR 200 
FTIR) spectrophotometer. The samples were prepared by 1 
mg of drug is mixed with the 100 mg of spectroscopic grade 
of KBr and triturated for uniform mixing. The thin and 
transparent pellet is prepared by applying 150 lbs pressure. 
The prepared pellet is exposed to IR beam and spectra are 
recorded by using FTIR scanned between 450-4000cm1[12-
13]. 
Thickness: 
The thickness of the tablets is measured by vernier calipers 
and it is expressed in mm. The outcomes are given in the 
table no.04 
Hardness:  
Tablets require strength or hardness to withstand 
mechanical shocks of handling in manufacture, packing and 
shipping. Tablet hardness was measured by Monsanto 
hardness tester and results are expressed in Kg/cm2.The 
outcomes are given in the table no.04 
Weight variation test: 
20 tablets were weighed individually. Average weight was 
calculated from the total weight of all tablets. The individual 
weights were compared with the average weight. The 
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percentage difference in the weight variation should be 
within the permissible limits (±7.5%). The percent deviation 
was calculated using the following formula.The acceptance 
limits are as per Indian pharmacopoeia (I.P) [14-15]. 
 
 
 
Friability:  
It was performed in Roche friabilator where the tablets were 
subjected to the combined effect of abrasion and shock by 
utilizing a plastic chamber that revolves at 25 rpm dropping 
the tablets at a distance of six inches with each revolution in 
chamber. Pre weighted samples of 20 tablets were placed in 
the Friabilator, which is then operated for 100 revolutions. 
The tablets are then dusted and reweighed [16]. Permitted 
friability limit is 1.0%. The percent friability was determined 
using the following formula-The outcomes are given in the 
table no.04 
 
 
Determination of drug content 
Twenty tablets were taken and triturated well. The quantity 
equivalent to 100mg of Alendronate was dissolved in 100ml 
of phosphate buffer pH 6.8 solutions on rotary shaker 
overnight. The solution was centrifuged and supernatant was 
collected. The absorbance was measured using UV-Visible 
spectrophotometer at 238nm [17]. The outcomes are given 
in the table no.04 
Microenvironment pH study  
The microenvironment pH of the tablets was determined by 
the method proposed by Bottenberg, et al, 1991. The tablets 
were allowed to swell for 2 hours in 2ml of pH 6.8 phosphate 
buffer (pH 6.8±0.05) in specially fabricated glass tubes and 
microenvironment pH was measured by placing the pH 
electrode in contact with the surface of the tablet and 
allowing it to equilibrate for 1 minute [18-19]. The outcomes 
are given in the table no.05 
Swelling index  
 It is evaluated by determination of percent of swelling. Each 
tablet was weighed (W1) and placed in petri dish with 5ml of 
phosphate buffer pH6.8 and incubated at 370c for 
predetermined times. After placing the formulation for 
specified time, the tablets were wiped off to remove excess of 
surface water by using filter paper and again reweighed 
(W2) [20]. The result  outcomes are given in the table no.05 
  
  
Where,  
W 1=Initial weight of the tablet.  
W2= Weight of tablet after swelling time interval 
Determination of the In vivo residence time  
The In vivo residence time was found using a locally modified 
USP disintegration apparatus. The disintegration medium 
was composed of 800 ml pH 6.8 phosphate buffer 
maintained at 37°C. The sheep buccal tissue was tied with 
thread to the central stand. The buccal tablet was hydrated 
with 0.5ml of pH 6.8 phosphate buffer and then the hydrated 
surface was brought in contact with the mucosal membrane 
[21-22]. The tissue was allowed to run in such way that the 
tablet completely immersed in the buffer solution at the 
lowest point and was out at the highest point. The time taken 
for complete erosion or dislodgment of the tablet from the 
mucosal surface was noted. 
In Vitro drug release study: 
 In vitro drug release study of mucoadhesive tablets were 
performed using standard USP dissolution apparatus type II 
(lab india USP XXII). The bowls of the dissolution apparatus 
was filled with 500ml of phosphate buffer pH 6.8 and 
maintained at a temperature of 37±0.50C. For each time 
interval 5ml sample withdrawal and replacement of fresh 
media at predetermined time interval. The collected samples 
were filtered through the 0.45μm pore filter [23-24]. The 
samples were analyzed for drug content using double beam 
UV spectrophotometer at 238nm.  
Drug Release Kinetics   
To examine the release mechanism of alendronate from the 
prepared buccoadhesive tablets, the results were analyzed 
according to the following equation:  
        fi=Mt    Ktn                              
Where t   ∞ is the fractional drug released at time t, k is a 
kinetic constant incorporating structural and geometrical 
characteristics of drug / polymer system [device], and n is 
the diffusion exponent that characterizes the mechanism of 
drug release. Drug release is generally expressed by Fickian 
diffusion mechanism. For non-fickian release, the n value 
falls between 0.5 and 1.0 (0.5< n< 0.89) whereas in the case 
super case II transport n > 0.89 [25]. Data of the in-vitro 
release was fit in to different equations and kinetic models to 
explain the release kinetics of drug from buccal tablets. The 
kinetic models used were zero-order equation, first order 
equation , higuchi equation and korsemeyer-peppas 
equation. 
Stability studies: Stability studies were performed at a 
temperature of 25±20c and 65±5%RH and 40±20c and 
75±5%RH, over a period of three months (90 days) for the 
optimized buccal tablet i.e., formulation F11.Sufficient 
number of tablets were packed in amber colored screw  
capped bottles and kept in stability chamber maintained at  
400±10C & 75 % RH.  Samples were taken at monthly 
intervals for drug content estimation [26-27]. At the  end  of  
three  months  period, dissolution test and drug content 
studies were performed  to  determine  the  drug  release  
profiles and drug content. 
RESULTS AND DISCUSSION: 
Preformulation Study: 
Table 02. Results of identification tests of drug 
S.No Parameter Drug 
1 Colour Fine White powder 
2 Odor Odorless 
3 Taste Tasteless 
4 Appearance Crystalline powder 
5 Melting Point 2340 c 
  
Compatibility studies  
The FTIR spectroscopy is used for identifying both organic 
and inorganic chemicals which utilized to quantify some 
components of an unknown mixture and can be used to 
analyze liquids, solids and gases. The FT-IR spectrum didn’t 
showed presence of any additional peaks for new functional 
                       Individual weight – Average weight 
% Deviation = ------------------------------------------- X100 
                                    Average weight 
% Friability= (initial weight-final weight/initial weight) x100 
% 𝑠𝑤𝑒𝑙𝑙𝑖𝑛𝑔 𝑖𝑛𝑑𝑒𝑥 = (𝑊2) − (𝑊1) X 100 
                                         𝑊1 
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groups in optimize formulation F11 indicating there is no chemical interaction between drug and the used polymers. 
 
 
Fig 1: FTIR Spectra of alendronate pure drug 
 
Fig 2: FTIR spectra of alendronate sodium optimized formulation 
 
 Characterization of blend: 
The blends for buccoadhesive tablets were characterized 
with respect to angle of repose, bulk density, tapped density, 
carr’s index, and hausner’s ratio. Angle of repose was less 
than 30° and Carr’s index values were less than 20 for the 
blend of all the batches indicating excellent to good 
flowability and compressibility. Hausner’s ratio was less than 
1.25 for all the batches indicating excellent flow properties. 
 
Table 03: Physical properties of Pre-compression blend 
Formulations 
Code 
Angle of repose Bulk Density 
(g/mL) 
Tapped Density 
(g/mL) 
Carr’s Index (%)   Hausner’s ratio 
F1 25.90±0.29 0.35±0.045 0.41±0.025 14.63±1.44 1.17±0.034 
F2 27.20±0.75 0.32±0.025 0.38±0.071 15.79±1.21 1.19±0.022 
F3 29.50±0.69 0.31±0.012 0.36±0.045 16.67±1.38 1.20±0.041 
F4 26.40±0.87 0.38±0.038 0.37±0.042 16.22±0.87 1.19±0.055 
F5 30.20±1.27 0.44±0.018 0.46±0.024 15.25±1.67 1.15±0.028 
F6 27.40±0.43 0.43±0.055 0.51±0.027 15.69±1.12 1.19±0.061 
F7 28.60±0.29 0.34±0.041 0.41±0.034 17.07±1.56 1.21±0.074 
F8 29.30±0.41 0.37±0.023 0.44±0.027 15.91±1.33 1.19±0.034 
F9 30.50±1.38 0.42±0.22 0.51±0.017 16.00±1.41 1.19±0.021 
F10 27.90±0.77 0.36±0.044 0.43±0.034 16.28±0.87 1.19±0.037 
F11 26.50±0.44 0.46±0.027 0.54±0.037 14.81±0.92 1.17±0.047 
F12 27.30±0.52 0.44±0.031 0.51±0.083 13.73±1.85 1.16±0.012 
*Average of three observations (n=3)     *All the values are expressed as mean ± SD 
Physical evaluation of buccoadhesive tablets: 
The results of physical evaluation of buccoadhesive tablets 
are given in below table. All the tablets of different batches 
complied with the official requirements of uniformity of 
weight as their weights varied between 297 and 310 mg. The 
hardness of the tablets ranged from 4.0-4.4 kg/cm2 and the 
friability values were less than 0.5% indicating that the 
buccoadhesive tablets were compact and hard. The 
thickness of the tablets ranged from 3.70-3.78 mm. All the 
formulations satisfied the content of the drug as they 
contained 98 to 101 % of alendronate and good uniformity 
in drug content was observed. Thus all the physical 
attributes of the prepared tablets were found be practically 
within control. 
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Table 04: Post formulation parameters of alendronate sodium buccoadhesive tablets 
Formulation. 
Code 
Hardness 
(kg/cm2) 
Thickness 
(mm) 
Weight 
(mg) 
Friability 
(%) 
Drug content 
(%) 
F1 4.3±0.31 3.71±0.26 304±1.45 0.40±0.08 99.2±0.45 
F2 4.2±0.64 3.75±0.61 310±1.15 0.39±0.11 100.3±0.72 
F3 4.1±0.26 3.72±0.17 308±1.86 0.20±0.02 98.63±0.27 
F4 4.2±0.24 3.70±0.25 297±1.84 0.22±0.07 99.02±0.37 
F5 4.4±0.46 3.74±0.31 298±1.98 0.21±0.04 99.24±1.54 
F6 4.5±0.41 3.76±0.22 301±0.87 0.26±0.14 98.56±2.35 
F7 4.4±0.31 3.73±0.34 300±1.12 0.31±0.11 100.3±0.74 
F8 4.3±0.54 3.72±0.12 306±1.76 0.38±0.06 101.6±0.58 
F9 4.2±0.27 3.75±0.51 305±1.48 0.32±0.07 98.6±0.32 
F10 4.0±0.45 3.72±0.33 304±1.67 0.36±0.12 97.4±0.84 
F11 4.0±0.28 3.78±0.41 299±1.38 0.21±0.08 99.64±0.46 
F12 4.3±0.18 3.74±0.24 303±1.95 0.26±0.04 100.1±1.17 
*Average of three observations (n=3)      *All the values are expressed as mean ± SD 
 
 Microenvironment pH study: 
The surface pH of all formulations was found to be within ±1 
units of neutral pH. The values are tabulated in the table no 
05. As the pH is neutral it would not cause any irritation in 
buccal cavity.          
Swelling Index: 
 The swelling behavior of a buccal adhesive system is an 
important properties uniform and prolonged release and 
effective mucoadhesion. The swelling index study indicated 
that the rate of swelling was directly proportional to Sodium 
alginate and polymer content. Swelling index was calculated 
with respect to time. The swelling index gives an indication 
of the relative moisture absorption capacities of polymers 
and whether the formulations maintain their integrity after 
moisture absorption. The results of present formulation 
were tabulated in the table no. 05. 
Mucoadhesion time: 
 In vivo residence time was determined by using sheep 
buccal mucosa. The mucoadhesion time is important to 
know how long the tablet could able to stick to the buccal 
mucosa. This adhesion time relates to the release rate of 
drug. The bioadhesive tablet is important for good 
mucoadhesion. bioadhesion characteristics are affected by 
the type and ratios of bioadhesive polymers The results 
were tabulated in the table no. 05. 
  
Table 05: Surface pH,swelling index and mucoadhesion time 
Formulation 
Code 
Surface pH Swelling Index Mucoadhesion time 
F1 6.4±0.31 140            1hrs  32min 
F2 7.2±0.24 120 2hrs 03min 
F3 6.5±0.76 145 1hrs 45min 
F4 7.1±0.33 130 3hrs 40min 
F5 6.6±0.18 160 3hrs 50min 
F6 6.5±0.61 150 3hrs 35 min 
F7 6.8±0.38 165 4hrs 02min 
F8 6.4±0.24 150 5hrs 39min 
F9 6.1±0.85 120 4hrs 30min 
F10 6.4±0.21 155 4hrs 47min 
F11 6.6±0.41 165 6hrs 45min 
F12 6.2±0.37 150 5hrs 55min 
 
In-vitro drug release study: 
The In-vitro drug release study has been done for various 
formulations (F1-F12). The different ratios of polymers were 
used. The results shown that as the proportion of polymers 
in the formulation increases, cumulative percent drug 
released was found to be reduced. 
             
Table 06: In-vitro release of formulation F1-F6 
 % Drug release 
Time(Hrs.) F1 F2 F3 F4 F5 F6 
0 0 0 0 0 0 0 
0.5 32.1 21.1 23.8 25.1 29.2 22.6 
1 57.2 48.3 46.4 50.8 46.8 43.1 
2 98.6 71.2 70.8 73.4 70.6 68.1 
4  99.7 98.6 84.3 85.1 87.2 
5    100.1 100.8 99.8 
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Table 07: In-vitro release of formulation F7-F12 
% Drug release 
Time (Hrs) F7 F8 F9 F10 F11 F12 
0 0 0 0 0 0 0 
0.5 28.3 18.6 19.8 20.8 16.2 18.1 
1 51.7 30.9 29.1 33.1 27.1 31.2 
2 63.2 48.6 44.3 49.2 38.3 45.4 
3 86.4 59.3 63.4 69.4 56.1 60.6 
4 97.4 76.3 80.3 78.1 64.8 71.8 
5  83.4 100.1 99.8 73.1 85.6 
6  100.7   84.3 99.5 
7     97.6  
 
 
 
Fig 3: Dissolution graph for formulations F1-F6 
 
Fig 4: Dissolution graph for formulations F7-F12
 
Release kinetics: 
For analyzing the release mechanism, the data obtained were 
fitted to various kinetic equations of zero order, first order, 
higuchi model and korsemeyer-peppas model. The 
regression coefficient was calculated. From the data, it can be 
seen the formulation, F11 have displayed zero order release 
kinetics. From Peppas model it is evident that the drug is released 
by non-Fickian diffusion mechanism. The data of regression 
coefficient of different kinetic models were summarized in 
table no.08. 
 
Table 08: Release kinetics for the optimized formulation F11 
 ZERO FIRST HIGUCHI PEPPAS 
 (% CDT VsT)  (Log % remain VsT) %CDT Vs√T Log C Vs Log T 
Slope 12.901 -0.18208893 36.88339627 1.076787696 
Intercept 9.980166667 2.106740204 -7.29768667 1.100314385 
R 2 0.975636613 0.824537248 0.971885439 0.490727483 
 
Stability studies:  
Results from stability studies indicate that the formulated 
Alendronate bucoadhesive tablet are stable for a period of 3 
months under 2 different conditions at 25 25±20c and 
65±5%RH and 40±20c and 75±5%RH.There were no remarkable 
changes were observed during the period of storage.
               
Table 09: Release kinetics for the optimized formulation F11 
 
 
 
     Time 
 
 
 
Colour 
Assay Cumulative % drug release 
 
±20c and 
65±5%RH 
 
40±20c and 
75±5%RH 
25±20c and 
65±5%RH 
40±20c and 
75±5%RH 
0 days    White 99.64 99.64 97.60 97.60 
30 days    White 99.06 99.42 97.02 97.01 
60 days    White 98.51 98.00 97.01 96.89 
90 days    White 98.46 97.41 96.88 96.77 
   
 
  
 
 
 
 
 
 
 
   
 
  
 
F7 
F8 
F9 
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CONCLUSION: 
The study performed on “Development and evaluation of 
mucoadhesive buccal tablets of alendronate” reveals 
following conclusion. The mucoadhesive buccal tablets of 
alendronate could be prepared using ethyl cellulose and 
carbopol by direct compression method. The prepared 
mucoadhesive buccal tablets subject ted to FTIR study 
suggested that there was no drug-polymer and polymer-
polymer interaction. The formulation F11 show the tablets 
were in acceptable range in all factors like friability, 
hardness, pH. The formulation F11 showed good swelling up 
to 6hr 45min in phosphate buffer pH6.8 maintaining the 
integrity of formulation which is required for bioadhesion. In 
vitro bioadhesive strength & in vitro release studies showed 
that formulation F11 showed optimum bioadhesive & 
exhibited optimum drug release 97.6% in 7hr. Kinetics 
results shown in table no-08 reveals that the F11 
formulation follows zero order kinetics as correlation 
coefficient (r2) values are higher than that of first- order 
release kinetics.  The optimize formulation F11 show drug is 
released by non-Fickian diffusion mechanism. The stability 
studies of formulation F11 prepared mucoadhesive buccal 
tablets of alendronate were stable. Hence the mucoadhesive 
buccal tablets of alendronate can be prepared with enhanced 
bioavailability and prolonged therapeutic effect for the 
better management of hypercholesterolemia patients. The 
study conducted so far reveals a promising result suggesting 
scope for pharmacodynamics and pharmacokinetic 
evaluation. 
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